Background In the absence of highly effective antiviral therapies against SARS-CoV-2, it is
crucial to counter the known pathophysiological causes of severe COVID-19. Evaluating the …

Interleukin-6 (IL-6) is a cytokine with multifaceted effects playing a remarkable role in the
initiation of the immune response. The increased level of this cytokine in the elderly seems …

Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by
severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe …

Background Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID‐19)
affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of …

Pathogenesis SARS-CoV-2 spreads through respiratory droplet transmission as well as
contaminated objects or surfaces and enters host cells via the functional cell receptor ACE2 …

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Introduction The pathogenic and highly transmissible etiological agent, SARS-CoV-2, has
caused a serious threat COVID-19 pandemic. WHO has declared the epidemic a public …

Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19)
includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab …